New Jersey · 81207

Translocation Analysis (bcr/abl1) Minor Breakpoint in New Jersey

New Jersey Medicare Avg
$141.66
0% above national avg
National Medicare Avg
$141.61
All states combined
Billed Charge (NJ)
$264.31
What providers submit
Est. Commercial (NJ)
$361.24
National avg: $317.20
Est. Cash / Self-Pay (NJ)
$178.93
Typical self-pay discount

Estimated using RAND 2024 commercial-to-Medicare ratios. Actual prices vary by insurer, plan, and facility.

3.9K
Services in NJ
9
Providers
N/A
Min Payment
N/A
Max Payment

Top Providers in New Jersey

Provider Medicare Services
Bioreference Health, Llc $141.60 2.7K
Quest Diagnostics Incorporated $141.94 511
Laboratory Corporation Of America... $141.94 433
Pathline , Llc $141.02 212
Siparadigm Llc $141.94 79
Cairo Diagnostics Nj, Llc $141.94 13

New Jersey Pricing in Context

In New Jersey, CPT code 81207 (Translocation Analysis (bcr/abl1) Minor Breakpoint) carries an average Medicare payment of $141.66 — 0% above the national benchmark of $141.61. 9 providers across the state submitted claims for this procedure in 2023, performing 3.9K total services. Individual payments in NJ ranged from N/A at the low end to N/A at the high end, reflecting differences in provider setting (office vs. facility), modifiers, and the specific geographic locality code applied within the state.

The average billed charge in New Jersey is $264.31, which is the figure uninsured patients would most likely encounter before any negotiation or charity discount. Medicare, by statute, only reimburses the allowed amount — the balance between billed and paid is written off under provider participation agreements. Insured patients generally pay a negotiated rate that falls between these two figures; the exact amount depends on plan design, deductible status, and in-network participation. Because New Jersey sits above the national Medicare average, commercial rates in the state may also run higher than the US median.

Using RAND 2024 commercial-to-Medicare ratios for Laboratory procedures, the estimated commercial insurance price in New Jersey lands near $361.24, with self-pay cash prices typically around $178.93. Before scheduling, patients can request a Good Faith Estimate under the No Surprises Act, compare cash rates from hospital Machine-Readable Files, and confirm whether the provider is in-network with their specific plan. This page presents CMS reference data for informational use; it does not constitute medical or financial advice.

Frequently Asked Questions

How much does Translocation Analysis (bcr/abl1) Minor Breakpoint cost in New Jersey?

The average Medicare payment for Translocation Analysis (bcr/abl1) Minor Breakpoint in New Jersey is $141.66, which is 0% above the national average of $141.61. Providers in NJ typically bill $264.31 for this procedure.

What does Translocation Analysis (bcr/abl1) Minor Breakpoint cost with insurance in New Jersey?

With commercial insurance in New Jersey, Translocation Analysis (bcr/abl1) Minor Breakpoint costs an estimated $361.24. Without insurance, the estimated cash price is $178.93. These estimates are based on RAND 2024 commercial-to-Medicare ratios and vary by insurer, plan, and facility.

How many providers perform Translocation Analysis (bcr/abl1) Minor Breakpoint in New Jersey?

9 providers in New Jersey billed Medicare for Translocation Analysis (bcr/abl1) Minor Breakpoint in 2023, performing 3.9K total services. Medicare payments ranged from N/A to N/A depending on the provider.

Is Translocation Analysis (bcr/abl1) Minor Breakpoint cheaper in New Jersey than the national average?

No — Translocation Analysis (bcr/abl1) Minor Breakpoint costs 0% above the national average in New Jersey. The state average Medicare payment is $141.66 compared to $141.61 nationally. Factors like local cost of living, provider competition, and regional Medicare fee schedules all influence state-level pricing.

Related

Data sourced from the CMS Medicare Physician and Other Practitioners dataset. See our methodology for details. Retrieved and formatted by PlainProcedure Editorial